Home / News / Clive Gringras elected to Early Detection of Neurodegenerative...

Clive Gringras elected to Early Detection of Neurodegenerative diseases initiative Board led by former UK Prime Minister

11 November 2020

International law firm CMS is pleased to announce that Clive Gringras, CMS partner and Head of Technology, Media and Telecommunications, has been appointed to the Board of Early Detection of Neurodegenerative diseases (EDoN), a pioneering global initiative spearheaded by the charity Alzheimer’s Research UK. 

EDoN aims to develop a digital device to radically improve the detection of diseases that cause dementia by investigating a range of very subtle behavioural changes that emerge years before problems such as memory loss start to affect a person’s day-to-day life. Sleep, gait, eye movements, speech patterns and mood can all be affected in the very early stages of the diseases that cause dementia. A digital device that can measure, combine and analyse changes in these behaviours has huge potential to detect a disease in its earliest stages, and could transform efforts to develop new treatments.

The new EDoN Board comprises 10 prominent experts, including Clive, and is chaired by former UK Prime Minister and President of Alzheimer’s Research UK, the Rt Hon David Cameron. The Board oversees the project, approves the project strategy and plans, and ensures that the provided funding is spent wisely. It offers expert guidance that will help to drive the initiative forward and includes representatives from the world of data science, Med Tech, clinical research, pharma and philanthropy. 

Clive Gringras said: “It is an honour to be appointed to the EDoN Board. Combined with my role as a pro bono legal adviser to EDoN, it is a privilege to have this opportunity to offer even greater support to Alzheimer’s Research UK in their efforts to detect dementia diseases as early as possible, a cause that is sadly very close to my heart. I look forward to working closely with the other EDoN Board members.”

Ian Wilson, Deputy Chief Executive of Alzheimer's Research UK, added: “We are delighted that Clive has joined the EDoN Board. Clive’s expertise and connections as our legal adviser, along with CMS’s wider pro bono support, have been and continue to be invaluable in steering us through legal technicalities and compliance issues. Our work towards early detection and transforming lives stands to benefit even more with Clive now a member of the EDoN Board. Thanks to the fantastic support of Clive and our ongoing partnership with CMS, which we are incredibly grateful for, we will make breakthroughs in dementia research possible.”

Dementia affects over 50 million people around the world, and there is currently no way to prevent, treat or cure the underlying diseases. Alzheimer’s disease is responsible for around two thirds of dementia cases, but other diseases can cause similar memory and thinking problems. Partners in EDoN include world-leading universities, technology companies and data science institutes, such as the Alan Turing Institute. The initiative is the largest of its kind to use digital health technology for the early detection of diseases like Alzheimer’s.